CARGO Therapeutics, Inc. (NASDAQ:CRGX) Holdings Reduced by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD lowered its holdings in CARGO Therapeutics, Inc. (NASDAQ:CRGX - Free Report) by 9.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,436,171 shares of the company's stock after selling 258,135 shares during the period. Price T Rowe Associates Inc. MD owned about 5.29% of CARGO Therapeutics worth $35,131,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. American Century Companies Inc. purchased a new position in shares of CARGO Therapeutics during the 4th quarter valued at approximately $474,000. Barclays PLC boosted its stake in CARGO Therapeutics by 226.7% during the 3rd quarter. Barclays PLC now owns 56,354 shares of the company's stock valued at $1,039,000 after acquiring an additional 39,102 shares during the last quarter. Vanguard Group Inc. grew its holdings in CARGO Therapeutics by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 2,084,515 shares of the company's stock worth $30,059,000 after acquiring an additional 22,286 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of CARGO Therapeutics by 74.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 15,007 shares of the company's stock worth $277,000 after purchasing an additional 6,426 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of CARGO Therapeutics by 7.2% in the 4th quarter. Wellington Management Group LLP now owns 2,190,811 shares of the company's stock valued at $31,591,000 after purchasing an additional 148,088 shares in the last quarter. Institutional investors and hedge funds own 93.16% of the company's stock.

Wall Street Analysts Forecast Growth

CRGX has been the subject of a number of research reports. William Blair downgraded CARGO Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, January 30th. Jefferies Financial Group lowered CARGO Therapeutics from a "buy" rating to a "hold" rating and decreased their target price for the stock from $32.00 to $3.00 in a research report on Thursday, January 30th. Truist Financial lowered CARGO Therapeutics from a "buy" rating to a "hold" rating and dropped their price target for the company from $32.00 to $7.00 in a research report on Thursday, January 30th. HC Wainwright lowered shares of CARGO Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. downgraded shares of CARGO Therapeutics from an "overweight" rating to an "underweight" rating in a research report on Thursday, January 30th. One analyst has rated the stock with a sell rating and six have given a hold rating to the stock. Based on data from MarketBeat, CARGO Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $15.00.

CARGO Therapeutics Trading Down 2.4 %

CRGX traded down $0.10 during trading on Tuesday, reaching $4.13. 47,524 shares of the company were exchanged, compared to its average volume of 514,109. CARGO Therapeutics, Inc. has a 52 week low of $3.00 and a 52 week high of $25.45. The firm has a 50 day moving average of $4.19 and a 200 day moving average of $10.36. The stock has a market cap of $190.43 million, a P/E ratio of -0.97 and a beta of 0.47.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.